Inmune Bio Inc. · NASDAQ:INMB
Inmune Bio — Investor Presentation (November 2025)
32 slides from Inmune Bio's investor presentation, Nov 10, 2025
Slide 1: Corporate Presentation November 2025
1 Corporate Presentation November 2025 NASDAQ: INMB Modulating the Innate Immune System to Transform Inflammation - Driven Disease
Slide 2: Forward-Looking Statements
2 FORWARD - LOOKING STATEMENTS This presentation contains “forward - looking statements” Forward - looking statements reflect our current view about future events. When used in this presentation, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of
Slide 3: Overview and Company Snapshot
3 Overview Clinical - stage biotechnology company developing next - generation immunotherapies targeting innate immune dysfunction in rare pediatric inflammatory disease and inflammatory neurologic disease. Key Programs INmune Bio – Company Snapshot FL | London, UK NASDAQ: INMB | Boca Raton, $1.87 S
Slide 4: Late-Stage Pipeline Across Inflammation & Immunology
4 Late - Stage Pipeline Across Inflammation s Immunology Filing / Phase 3 Phase 2 Phase 1 Pre - clinical Indication / Patient Pop (US&EU) Program/Platform RPDD + ODD Received MAA 2026 → BLA 2026 RDEB (pediatric, ultra - rare) (4K) CORDStrom EOP2 Q1 2026 → Phase 3 2027 Early Alzheimer's Disease with
Slide 5: Milestones in 2026–2027
5 Milestones in 2026 – 2027* Clear regulatory pathway and late - stage execution across rare disease and Alzheimer’s Q1 2026 Mid - 2026 Late - 2026 2027 XPro End - of - Phase - 2 FDA meeting CORDStrom MAA (UK) CORDStrom BLA (US) First Marketing Filing FDA Phase 3 Align Regulatory Clarity Enrichment
Slide 6: Robust and Growing Intellectual Property Estate
*Information as of October 8, 2025, dates and IP are subject to 6 change. See “Forward - Looking Statements” Robust and Growing Intellectual Property Estate CNS MoT (US; EU) e.g., US 11,365,229 PTE CoM (global) e.g., WO 2024/030569 CoM (global) e.g., WO 2025/189204 MoT (US; EU; AU; CA; CN; JP; KR) e
Slide 7: CORDStrom for EB
7 CORDStrom for EB Off - the - shelf allogeneic, pooled mesenchymal stromal cell (MSC) platform
Slide 8: CORDStrom – a Mesenchymal Stromal Cell (MSC) Platform
8 CORDStrom – a Mesenchymal Stromal Cell (MSC) Platform Mechanisms Of Action What is CORDStrom ? • Suppression of inflammation: RDEB/EB, OA, trauma, etc • Pooled, allogeneic donor, umbilical cord - derived Mesenchymal Stromal/Stem Cell (MSC) product (minimum four donors) • Immunomodulation: Autoimmu
Slide 9: Why CORDStrom Succeeds: Always Developed as a Drug
• CORDStrom Source: Umbilical Cord Tissues from multiple donors. • CORDStrom Identity : CD73/90/105 plus CD10/29/44/142/146/166/200/271 and MSCA - 1. MoA for each indication. • CORDStrom Homogeneity : Pooled donors create reproducible products with greater expansion potential. Individual donor selec
Slide 10: RDEB – An Ultra-Rare Systemic Disease with No Approved Systemic Treatments
10 RDEB – An Ultra - Rare Systemic Disease with No Approved Systemic Treatments *Recessive Dystrophic Epidermolysis Bullosa (RDEB); Quality of Life (QOL) • RDEB is a severe form of epidermolysis bullosa (EB), a rare disease that causes severe skin fragility, itch and chronic pain caused by mutations
Slide 11: RDEB Disease Progression
RDEB Disease Progression Journal of —_— 7 Dermatology and Venereology ¥ SclenceAssict Prospective | Open Access The Natural History of Severe Recessive Dystrophic Epidermolysis Bullosa — 4 Phases Which May Help Determine Different Therapeutic Approaches Bageta ML'*, Yerlett N?, McGrath JA’, Mellerio
Slide 12: Phase II MissionEB Trial Design
Phase 2 Mission EB Trial Double blinded placebo control study of Mesenchymal Intravenous Stromal cell Infusions in children with recessive dystrophic Epidermolysis Bullosa (MissionEB) | Group 1 [Mscs | MSCs Placebo || Placebo Aaaipiised pamanyana Stop/Go key secondary outcome review for data for NHS
Slide 13: Quantitative Results – Phase II Preliminary Analysis
Itch improved at 3 months and remained stable at 6 months. 13 Quantitative Results – Phase II Preliminary Analysis - 30 - 20 - 10 0 mITT severe & intermediate population Mean (%of range) - 30 - 20 - 10 0 mITT <10yr severe & intermediate population Mean (%of range) - 25 - 20 - 15 - 10 - 5 0 mITT Inte
Slide 14: ISCOREB Improvement Scores – Patient Reported Data
14 ISCOREB Improvement Scores – Patient reported data Group 1 at 3 and 6 months Skin Eye Joint Mouth Site - 5 0 5 10 15 20 Pain indicies CS 3m Placebo 3m CS 6m Placebo 6m Improvement Score Eating Bowel - 5 0 5 10 15 20 Gastrointestinal symptoms Site Improvement Score - 20 - 10 0 10 20 30 Wellbeing S
Slide 15: Qualitative Results – Phase II
15 Qualitative Results – Phase II
Slide 16: Conclusion
16 Conclusion • With itch reduction over time IscorEB scores have also improved in both RDEB severe cohort and intermediate • There is large improvement in iscorEB scores in RDEB - S cohort at month - 6 with improvement in overall score, patient C clinician scores and skin score • The observed skin
Slide 17: Final Statements
• CORDStrom has proven beneficial treatment with no safety signals in patients with RDEB from age 6 months • Intermediate and younger patients under the age of 10 saw the greater effect with improvement of their skin, pain and itch • Severe and older patients over 10 did not show changes in their sk
Slide 18: CORDStrom for RDEB: Path To Market
CORDStrom for RDEB: Path To Market FDA = Food and Drug Administration; MHRA, EMA = regulatory agencies in UK and EU; ODD = Orphan Drug Designation; MAA = Market Authorization Application; BLA = Biologics Licensing Application; RPDD = Rare Pediatric Disease Designation *Estimated dates subject to cha
Slide 19: CORDStrom: Rare Disease Therapy with Systemic Treatment Needs
CORDStrom : Rare Disease Therapy with Systemic Treatment Needs TAM = Total addressable market; Vyjuvek = Product of Krystal Biotech, Inc.; Filsuvez = Product of Chiesi Farmaceutici S.p.A.; Zevaskyn = Product of Abeona Therapeutics Inc. Anticipated treatment schedule • One treatment (2 doses over 14
Slide 20: CORDStrom Platform - Future Expanding Pipeline
20 CORDStrom Platform - Future Expanding Pipeline • Selection of PCS for disease - specific potencies • OA: TGF - b / IGF - 1 / FGF - 2 / HGF / PGE2 • EB: TSG6 / Wound healing / T cell suppression • SLE: B cell suppression / T cell suppression / Wound healing • Sjogren’s & R - I xerostomia: GDNF / W
Slide 21: Approaching Alzheimer's as an Immunologic Disease
21 Approaching Alzheimer’s as an Immunologic Disease
Slide 22: Millions of Patients in the US Need Better Solutions
22 Note: These figures are approximate and based on a synthesis of recent data from various sources including the Alzheimer's Association, National Institute on Aging (NIA), and peer - reviewed studies (circa 2020 - 2025). • MCI (Mild Cognitive Impairment): ~12 million (primarily all - cause MCI in
Slide 23: Strong Evidence for anti-TNF to Treat Alzheimer's Disease
23 Strong Evidence for anti - TNF to Treat Alzheimer’s Disease 1. Torres - Acosta N, et al. J Alzheimer’s Dis. 2020;78:619 – 626 8. Blasko et al. FASEB Journal. 1999, 13(1):63 - 68 2. Fillit H, et al. Neurosci Letters . 1991;129:318 - 320 9. Gorlovoy et al. FASEB Journal. 2009, 23(8):2502 - 2513 3.
Slide 24: XPro in Alzheimer's Disease: Rationale and Background
24 XPro TM in Alzheimer’s Disease: Rationale and Background Neuroinflammation in AD • Recognized contributor to disease progression in AD 1 • Associated with synaptic dysfunction/loss and cognitive impairment across the AD continuum 2 • Contributes to brain inflammation and damage in Alzheimer’s, wo
Slide 25: Phase 2 MINDFuL Trial Design
25 Key Enrollment Criterion □ Early AD (50 - 85 yrs) □ Amyloid positive □ CDR (0.5 or 1) □ MMSE > 22 □ Ecog >1.5 □ One Inflammatory Biomarker: □ hsCRP (1.5 mg/L) □ ESR (10 mmg/hr) □ HbA1c (6%) □ APOE4+ Baseline □ EMACC □ Cognition □ Function □ Blood □ MRI Baseline Week 6 □ EMACC Week 12 □ EMACC □ Co
Slide 26: XPro Halted Cognitive Decline in Highly Inflamed Alzheimer's Patients
26 XPro TM Halted Cognitive Decline* in Highly Inflamed Alzheimer’s Patients Change From Baseline Placebo XPro1595 EMACC: LS Mean Diff (SE): 0.086 (0.0603), 90% CI: - 0.0146, 0.1857 , p - value: 0.1594. CDR - SB: LS Mean Diff (SE): - 0.08 (0.307), 90% CI: - 0.593, 0.426 , p - value: 0.7859. NPI: LS
Slide 27: Enriched Population: Most Endpoints Favor Treatment with XPro
27 Enriched Population: Most Endpoints Favor Treatment with XPro TM Depicted as absolute effect sizes (Cohen’s D) Effect size (Cohen’s D) EMACC: Early and Mild Alzheimer's Cognitive Composite. ISRL: International Shopping List Delayed Recall. CDR - SB: Clinical Dementia Rating – Sum of Boxes. NPI: N
Slide 28: Why Did We Miss? Population Changes Due to Operational Limitations
28 Why Did We Miss? Population Changes Due to Operational Limitations Original Key Inclusion Criteria: Enriched Protocol • Age (60 - 85 years) • Diagnosis of mild AD (NIA - AA stage - 4) 1 • Amyloid - beta positive (Aβ+) • MMSE ≥ 22 • ≥ 2 blood biomarkers of inflammation Expanded Inclusion Criteria:
Slide 29: XPro: Safe, Effective, and Poised for Targeted Phase 3 Success
29 ARIA - E = amyloid - related imaging abnormalities - edema/effusions; ARIA - H=amyloid - related imaging abnormalities - microhemorrhages/hemosiderin deposits; SAF = Safety Analysis Set XPro : Safe, Effective, and Poised for Targeted Phase 3 Success ARIA - E Safety: • Zero cases of ARIA (a major
Slide 30: Execution Roadmap: Regulatory & Clinical Milestones
30 Execution Roadmap: Regulatory s Clinical Milestones CORDStrom (RDEB, rare pediatric) ✓ Phase 2 Pediatric Trial Completed ✓ RPDD / ODD Granted → MAA Submission (UK) – Mid 2026 → BLA Submission (US) – Late 2026 → PRV Eligibility & Launch Readiness – 2027 XPro (Early Alzheimer's, biomarker - enriche
Slide 31: Investment Highlights
31 x Two late - stage programs with strong safety and efficacy signals x First - in - class systemic therapy for RDEB and novel Alzheimer’s mechanism x Multiple near - term regulatory milestones driving value x Capital - efficient development model with strong partnerships Investment Highlights
Slide 32: For More Information
32 For More Information: INmune Bio Inc. 225 NE Mizner Blvd. Ste. 640 Boca Raton, FL 33432 (561) 710 - 0512 info@inmunebio.com INMB (Nasdaq)